Greece Gives Pancreatic Cancer Patients Early Access to Rasonque Before EU Approval

Patient and companion walking through a hospital corridor in Greece, illustrating early access to Rasonque for metastatic pancreatic cancer

MEDISEARCHER NEWS

Greece · Cancer treatment access · 14 November 2026

In brief

  • Greece began providing Rasonque (daraxonrasib) to selected patients with metastatic pancreatic cancer before the medicine received European Union marketing authorisation.
  • On 6 November 2026, Greek Health Minister Adonis Georgiadis confirmed that the first patients had received the treatment without paying for it themselves.
  • Greek healthcare organisations, including IFET, EOPYY and EOF, helped facilitate access through exceptional medicine-access arrangements.
  • Earlier reporting on 20 October indicated that initial patient-specific requests had already been approved and procurement was under way.
  • Update, 19 November 2026: The European Commission granted Rasonque marketing authorisation on 16 November, following the EMA’s positive recommendation on 15 October.
  • The Greek arrangement does not establish routine reimbursement, unrestricted availability or a commercial launch. National patient-access decisions remain separate from EU marketing authorisation.

ΣΥΝΟΨΗ ΣΤΑ ΕΛΛΗΝΙΚΑ

Σύντομη περίληψη στα ελληνικά

Η Ελλάδα ξεκίνησε να παρέχει το Rasonque (daraxonrasib) σε επιλεγμένους ασθενείς με μεταστατικό καρκίνο του παγκρέατος, πριν από την επίσημη έγκρισή του στην Ευρωπαϊκή Ένωση. Στις 6 Νοεμβρίου 2026, ο υπουργός Υγείας Άδωνις Γεωργιάδης επιβεβαίωσε ότι οι πρώτοι ασθενείς είχαν ήδη λάβει το φάρμακο χωρίς οικονομική επιβάρυνση.

Η πρόσβαση κατέστη δυνατή μέσω ειδικών διαδικασιών εισαγωγής και χορήγησης φαρμάκων, με τη συμμετοχή του ΙΦΕΤ, του ΕΟΠΥΥ και του ΕΟΦ. Σύμφωνα με προηγούμενες αναφορές, είχαν ήδη εγκριθεί αρχικά εξατομικευμένα αιτήματα ασθενών για την προμήθεια του φαρμάκου.

Ενημέρωση 19 Νοεμβρίου 2026: Η Ευρωπαϊκή Επιτροπή χορήγησε άδεια κυκλοφορίας στο Rasonque στις 16 Νοεμβρίου 2026, μετά τη θετική γνωμοδότηση της Επιτροπής Φαρμάκων για Ανθρώπινη Χρήση (CHMP) του Ευρωπαϊκού Οργανισμού Φαρμάκων (EMA) στις 15 Οκτωβρίου. Το φάρμακο έχει πλέον εγκριθεί σε επίπεδο Ευρωπαϊκής Ένωσης για ενήλικες με μεταστατικό αδενοκαρκίνωμα του παγκρέατος που έχουν λάβει τουλάχιστον μία προηγούμενη συστηματική θεραπεία.

Σημαντική διευκρίνιση: Η δωρεάν χορήγηση του Rasonque σε συγκεκριμένους ασθενείς δεν σημαίνει ότι το φάρμακο είναι γενικά διαθέσιμο στην Ελλάδα ή ότι έχει ενταχθεί στο κανονικό σύστημα αποζημίωσης. Η ευρωπαϊκή άδεια κυκλοφορίας δεν συνεπάγεται αυτόματα αποζημίωση ή άμεση πρόσβαση για όλους τους επιλέξιμους ασθενείς. Οι ασθενείς που ενδιαφέρονται για πιθανή πρόσβαση θα πρέπει να συμβουλεύονται τον θεράποντα ογκολόγο τους.

Greece began providing Rasonque (daraxonrasib), a targeted treatment for metastatic pancreatic cancer, to selected patients before the medicine received European Union marketing authorisation.

Update, 19 November 2026: The European Commission subsequently authorised Rasonque on 16 November 2026. The Greek early-access arrangements described below preceded that decision and remain distinct from routine national reimbursement. MediSearcher has published a separate report explaining Rasonque’s EU approval and what happens next for European patient access.

On 6 November 2026, Greek Health Minister Adonis Georgiadis confirmed that the first patients had received the treatment free of charge. The announcement represents a significant development in European patient access because it confirms that medicine has reached patients, rather than merely that individual access requests have been approved.

However, the arrangement is an exceptional, patient-specific access pathway. It does not mean Rasonque is generally available in Greece or routinely reimbursed, despite the subsequent EU-wide marketing authorisation.

Greece confirms first patients have received Rasonque

Greek Health Minister Adonis Georgiadis announced on 6 November that the first patients in Greece had received Rasonque, approximately two and a half months after the medicine received approval from the US Food and Drug Administration (FDA) on 26 August 2026.

The announcement followed a message from a patient who had exhausted other treatment options and received a first package of the medicine.

Georgiadis said Greece had moved quickly to make the treatment available to patients with an urgent medical need and confirmed that the initial recipients did not have to pay for the medicine themselves.

He highlighted the involvement of several organisations within the Greek healthcare system:

  • IFET: Greece’s pharmaceutical procurement and importation organisation, which played a central role in facilitating access to the medicine.
  • EOPYY: The National Organisation for Healthcare Services Provision, responsible for important aspects of publicly funded healthcare.
  • EOF: The National Organisation for Medicines, Greece’s national medicines regulatory authority.
  • ESY: Greece’s national healthcare system.

The announcement followed earlier reporting on 20 October that initial individual patient requests had already been approved and that arrangements to obtain the medicine were under way.

The 6 November confirmation therefore represents a further milestone: the transition from approved requests to actual treatment access.

How did patients receive Rasonque before EU approval?

European marketing authorisation and individual patient access are separate regulatory matters.

Under certain circumstances, national healthcare authorities can facilitate access to medicines that have not yet received standard marketing authorisation. Such arrangements are governed by national legislation and may involve exceptional importation or other patient-specific access mechanisms.

In Greece, the reported Rasonque arrangements involved individually authorised requests and the importation of medicine from abroad before European Commission authorisation was granted on 16 November.

This type of access can be particularly important for patients with metastatic pancreatic cancer whose disease has progressed despite previous treatment and who may have few remaining therapeutic options.

However, several limitations remain important:

  • The Greek announcement does not establish that every patient meeting the medicine’s clinical indication can obtain Rasonque.
  • The exact administrative requirements and eligibility criteria for additional requests have not been fully detailed in the public announcements.
  • The provision of medicine free of charge to the first patients does not establish a general national reimbursement policy.
  • No routine commercial launch or unrestricted nationwide supply arrangement has been confirmed.

Patients interested in possible access should consult their treating oncologist. Any exceptional access request must be assessed according to the patient’s medical circumstances and applicable national procedures.

What is Rasonque (daraxonrasib)?

Rasonque is an oral targeted cancer medicine developed by Revolution Medicines. Its active ingredient, daraxonrasib, is designed to inhibit signalling involving proteins in the RAS family, which are important drivers of tumour growth in many pancreatic cancers.

Daraxonrasib acts through a mechanism involving cyclophilin A, forming a complex that interferes with active RAS proteins and disrupts signalling pathways associated with cancer-cell growth and survival.

The medicine has been studied in patients with previously treated metastatic pancreatic cancer, including in the phase 3 RASolute 302 clinical trial.

Clinical findings demonstrated improvements in overall survival and progression-free survival compared with standard chemotherapy, supporting regulatory assessments in the United States and Europe.

Rasonque is not a cure for pancreatic cancer. Like other cancer treatments, it carries risks of adverse reactions. Reported side effects include rash, diarrhoea, nausea, vomiting and mouth inflammation.

Treatment decisions require specialist assessment of the potential benefits, risks, previous therapies and individual medical circumstances.

Where does Rasonque’s EU approval stand?

Rasonque received European Commission marketing authorisation on 16 November 2026.

On 15 October 2026, the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) recommended granting marketing authorisation for Rasonque.

The authorised European indication covers Rasonque as monotherapy for adults with metastatic pancreatic adenocarcinoma who have received at least one previous systemic treatment.

The recommendation followed the pivotal RASolute 302 Phase 3 trial, which demonstrated significant improvements in survival compared with standard chemotherapy. MediSearcher previously covered the clinical evidence, regulatory assessment and implications for European patients in its detailed report on Rasonque’s progress towards European approval for pancreatic cancer.

The CHMP’s positive opinion represented an important regulatory milestone, but it was not itself a European Union marketing authorisation.

The European Commission subsequently issued its legally binding decision on 16 November 2026, granting centralised marketing authorisation under registration number EU/1/26/2079.

The decision is recorded in the European Commission’s official Union Register of medicinal products.

Although Rasonque is now authorised in the European Union, individual countries generally need to complete relevant national pricing, reimbursement and healthcare-system processes before a new medicine becomes routinely available to patients.

Greece’s exceptional early-access arrangement demonstrates that selected patients may receive a medicine before these processes are complete. It does not mean the treatment has already received routine reimbursement throughout Greece.

For further information about the authorisation and national access implications, see MediSearcher’s November 2026 Rasonque EU approval report.

Does Greece’s announcement mean Rasonque is reimbursed?

No routine national reimbursement decision has been confirmed.

The Greek health minister’s announcement establishes that the first patients received Rasonque without paying for it themselves. This is an important patient-access outcome, particularly for a medicine intended to treat a serious and potentially life-threatening disease.

However, exceptional provision of a medicine at no cost to selected patients is different from formal inclusion in a national reimbursement system.

Routine reimbursement generally establishes a defined framework under which eligible patients can receive a medicine through the healthcare system, subject to applicable clinical and administrative criteria.

Exceptional access may instead depend on individual authorisations, specific procurement arrangements and the availability of medicine for particular patients.

Further announcements from Greek authorities will be needed to clarify whether the current arrangement will expand and how access will operate following the European Commission’s marketing authorisation.

What happens next for Rasonque in Europe?

With European Commission marketing authorisation granted on 16 November 2026, the next major milestones concern national decisions on pricing, reimbursement, clinical eligibility and the practical availability of treatment.

Rasonque is also subject to the European Union’s Health Technology Assessment Regulation. Its joint clinical assessment process is separate from EMA’s regulatory review and is intended to support national health technology assessments.

Italy’s medicines regulator, AIFA, confirmed on 18 November that it had begun a rolling assessment of daraxonrasib intended to accelerate national evaluation and facilitate equitable patient access. This does not establish an Italian reimbursement decision or routine availability. Further details are included in MediSearcher’s EU approval and European access report.

For Greece, important outstanding questions include:

  • Whether additional patients will receive Rasonque through the current exceptional access arrangements.
  • Whether Greek authorities will publish more detailed eligibility and application procedures.
  • How the existing access arrangements will operate following European marketing authorisation.
  • When Greece may reach formal pricing and reimbursement decisions for routine treatment access.

For patients elsewhere in Europe, Greece’s experience provides an example of early access being facilitated before standard regulatory and reimbursement processes have been completed.

However, it does not establish that equivalent access pathways are available in other countries or that individual patients elsewhere will qualify for similar arrangements.

What Greece’s early access means for pancreatic cancer patients

Greece’s confirmation that selected patients have received Rasonque represents a meaningful step from regulatory progress toward actual treatment access.

For patients with metastatic pancreatic cancer, particularly those whose disease has progressed after previous therapies, the possibility of receiving a newly developed treatment before routine European availability may be significant.

At the same time, the current arrangement remains individualised, and the public announcements do not establish a general entitlement to treatment.

Patients should discuss their treatment options with an oncology specialist familiar with their medical history and local medicine-access procedures. Prescription cancer medicines should not be obtained through unverified online suppliers.


Reviewed by: Dr Mattias Hagman, PhD

Editorial review: This article was reviewed against Greek healthcare reporting, European Medicines Agency regulatory information and manufacturer disclosures, with particular attention to the distinction between exceptional patient access, EU marketing authorisation and routine national reimbursement. The 19 November update incorporates the European Commission’s 16 November marketing authorisation and the subsequent shift towards national patient-access decisions.

Last reviewed: 19 November 2026

Sources and verification

MediSearcher reviewed the following sources when preparing and updating this article:

This article is provided for general informational purposes only and is not medical advice. Rasonque received European Union marketing authorisation on 16 November 2026, but routine availability and reimbursement remain subject to national arrangements. Exceptional access to medicines is subject to national legislation, individual clinical assessment and applicable administrative procedures. Patients should consult their treating oncology team for guidance about available treatments and access options.